Skip to main content
. 2018 Jun 5;68(4):554–560. doi: 10.1093/cid/ciy477

Table 2.

Characteristics of the Population Studied for Outcomes of Mycoplasma genitalium Treatment

Characteristic Macrolide Susceptible
(n = 77)
Macrolide Resistant (n = 167) Total
(N = 244)
Time to test of curea, d, median (IQR) 29 (25–41) 27 (22–32) 28 (22–35)
Age, y, median (IQR) 26.0 (22.9–30.9) 28.7 (25.6–34.4) 27.9 (24.5–33.0)
Sex/sexualityb
 Female 29 (37.7) 23 (13.8) 52 (21.3)
 Male, heterosexual 32 (41.6) 36 (21.6) 68 (27.9)
 MSM 16 (20.8) 108 (64.7) 124 (50.8)
Site of detectionc
 Cervix/vagina 24 (31.1) 21 (12.6) 45 (18.4)
 Urine 49 (63.6) 105 (62.9) 154 (63.1)
 Rectumd 4 (5.2) 41 (24.6) 45 (18.4)
HIV serostatus
 Negative 62 (80.5) 141 (84.4) 203 (83.2)
 Untested 15 (19.5) 10 (6.0) 25 (10.3)
 Positive 0 16 (9.58) 16 (6.56)
Asymptomaticc 18 (23.4) 43 (25.8) 61 (25.0)
Symptomatic 59 (76.6) 124 (74.3) 183 (75.0)
Clinical diagnosis
 Nongonococcal urethritis 31 (40.3) 78 (46.7) 109 (44.7)
 Contact of Mycoplasma genitalium 21 (27.3) 38 (22.8) 59 (24.2)
 Othere 5 (6.5) 28 (16.8) 33 (13.5)
 Vaginal discharge/bleeding 13 (16.9) 7 (4.2) 20 (8.2)
 Proctitis 3 (3.9) 12 (7.2) 15 (6.2)
 Cervicitis/PID 4 (5.2) 4 (2.4) 8 (3.3)

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; MSM, men who have sex with men; PID, pelvic inflammatory disease.

aTime to test of cure defined as days from the start of the second (resistance-guided) antibiotic.

bFemale includes 5 women who have sex with women. MSM includes 3 transgender women.

cNo. and proportion with macrolide-resistance mutations were: urine, 105 (68.2%); rectum, 41 (91.1%); cervix/vagina, 21 (46.7%); asymptomatic, 43 (70.5%); symptomatic, 124 (67.8%).

dIncludes 4 multisite infections.

eOther diagnoses included contact of chlamydia or gonorrhea (n = 9), urethral gonorrhea (n = 3), pelvic pain not diagnosed as PID (n = 3), dyspareunia (n = 2), dysuria (n = 2), anal itch/discharge (n = 4), vaginal candidiasis (n = 3), bacterial vaginosis (n = 2), balanitis (n = 2), pain with defecation (n = 2), epididymitis (n = 2).